<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33784279</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>2</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>[Safeness and reproductivity of a laparoscopic colorectal program in two tertiary care academic centers of South America].</ArticleTitle><Pagination><StartPage>141</StartPage><EndPage>149</EndPage><MedlinePgn>141-149</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.19001463</ELocationID><Abstract><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Evaluar la reproducibilidad y la seguridad de un programa de cirug&#xed;a colorrectal laparosc&#xf3;pica en dos centros de Sudam&#xe9;rica.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">Se realiz&#xf3; un estudio anal&#xed;tico-descriptivo. Se revisaron retrospectivamente los registros cl&#xed;nicos de pacientes sometidos a cirug&#xed;a videolaparosc&#xf3;pica colorrectal desde el a&#xf1;o 2012 hasta el a&#xf1;o 2018, en dos centros acad&#xe9;micos de tercer nivel argentinos. Se analizaron datos demogr&#xe1;ficos, indicaciones y tiempos quir&#xfa;rgicos, tasa de conversi&#xf3;n, evoluci&#xf3;n posoperatoria, morbimortalidad y resecabilidad oncol&#xf3;gica, y se compar&#xf3; con el abordaje convencional.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Se realizaron 505 cirug&#xed;as. La edad media de los pacientes fue de 63.4 a&#xf1;os y el 50.9% eran hombres. El tiempo operatorio medio fue de 175 minutos. La principal indicaci&#xf3;n fue c&#xe1;ncer de colon. La incidencia de conversi&#xf3;n fue del 9.5%. El promedio de ganglios por pieza quir&#xfa;rgica en patolog&#xed;a neopl&#xe1;sica fue de 15.9. La morbilidad fue del 35.4%, en su mayor&#xed;a complicaciones menores. La tasa de f&#xed;stulas fue del 11.7%. La mortalidad a 30 d&#xed;as fue del 2.5%.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">La cirug&#xed;a colorrectal laparosc&#xf3;pica podr&#xed;a representar una opci&#xf3;n segura y reproducible en un centro de tercer nivel de un pa&#xed;s en desarrollo.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the feasibility and safeness of a colorectal laparoscopic program in two centers form South America.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We retrospectively review the records of patients who underwent laparoscopic colorectal surgery from 2012 to 2018 in two tertiary care academic centers. Surgical indication, operative time, conversion rate, lymph nodes harvested, surgical margins and complications were analyzed. This results were then compared to the open approach.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We collected data from 505 patients, mean age 63.4, 50.9% male. The most frequent indication was colon cancer, mean operative time was 175 minutes. Conversion rate was 9.5%, mean nodes harvested was 15.9 with free resection margins in every case. Morbidity was 35.4% at 30 days, most of them were minor complications. The leak rate was 11.7 %. The 30-day mortality was 2.5%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The laparoscopic approach for colorectal surgery might represent a safe and feasible option in an tertiary care hospital from a developing country.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andrada</LastName><ForeName>Mart&#xed;n</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General, Hospital Privado Universitario de C&#xf3;rdoba, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollati</LastName><ForeName>Natalia P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General, Hospital Privado Universitario de C&#xf3;rdoba, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Signorini</LastName><ForeName>Franco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General, Hospital Privado Universitario de C&#xf3;rdoba, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado</LastName><ForeName>Pablo S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General, Hospital Privado Universitario de C&#xf3;rdoba, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moser</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General, Hospital Privado Universitario de C&#xf3;rdoba, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obeide</LastName><ForeName>Lucio R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General, Hospital Privado Universitario de C&#xf3;rdoba, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossini</LastName><ForeName>Alejandro M C</ForeName><Initials>AMC</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General, Hospital Privado Universitario de C&#xf3;rdoba, C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Seguridad y reproducibilidad de la cirug&#xed;a colorrectal laparosc&#xf3;pica en dos centros acad&#xe9;micos de tercer nivel en Sudam&#xe9;rica.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063128" MajorTopicYN="N">Tertiary Healthcare</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cirug&#xed;a laparosc&#xf3;pica</Keyword><Keyword MajorTopicYN="N">Colon</Keyword><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">C&#xe1;ncer colorrectal</Keyword><Keyword MajorTopicYN="N">Laparoscopic surgery</Keyword><Keyword MajorTopicYN="N">Recto</Keyword><Keyword MajorTopicYN="N">Rectum</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33784279</ArticleId><ArticleId IdType="doi">10.24875/CIRU.19001463</ArticleId><ArticleId IdType="pii">j89/2/141</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33284264</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>Suppl 2</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>Diagn&#xf3;stico inesperado en paciente con sospecha de GIST: infiltraci&#xf3;n g&#xe1;strica por mieloma m&#xfa;ltiple.</ArticleTitle><Pagination><StartPage>90</StartPage><EndPage>93</EndPage><MedlinePgn>90-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.20000566</ELocationID><Abstract><AbstractText>El mieloma m&#xfa;ltiple se caracteriza por la proliferaci&#xf3;n neopl&#xe1;sica medular de c&#xe9;lulas plasm&#xe1;ticas productoras de inmunoglobulina monoclonal. Un porcentaje peque&#xf1;o de pacientes presenta compromiso extramedular en forma de plasmocitoma, siendo la localizaci&#xf3;n m&#xe1;s habitual las v&#xed;as respiratorias altas. La afectaci&#xf3;n gastrointestinal es rara y la cl&#xed;nica asociada depender&#xe1; de la localizaci&#xf3;n, la extensi&#xf3;n y el mecanismo de infiltraci&#xf3;n. La afectaci&#xf3;n g&#xe1;strica en forma de tumoraci&#xf3;n tiene un aspecto y una sintomatolog&#xed;a similares a los de otras lesiones, por lo que es necesario realizar un diagn&#xf3;stico histol&#xf3;gico para un adecuado tratamiento. A continuaci&#xf3;n se presenta el caso de un mieloma m&#xfa;ltiple con afectaci&#xf3;n g&#xe1;strica. Multiple myeloma is characterized by medullary neoplastic proliferation of plasma cells producing monoclonal immunoglobulin. A small percentage of patients have extramedullary involvement in form of plasmacytoma, the most common location being the upper respiratory tract. Gastrointestinal involvement is rare and the associated symptoms will depend on the location, extent and mechanism of infiltration. Gastric involvement presents an appearance and symptoms similar to other lesions, so a histological diagnosis is necessary for proper treatment. This article presents the case of multiple myeloma with gastric involvement.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2020 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;-Gelonch</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General y Digestiva, Secci&#xf3;n de Cirug&#xed;a Esofagog&#xe1;strica y Obesidad, Hospital Universitario Donostia, San Sebasti&#xe1;n, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asensio-Gallego</LastName><ForeName>Jos&#xe9; I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General y Digestiva, Secci&#xf3;n de Cirug&#xed;a Esofagog&#xe1;strica y Obesidad, Hospital Universitario Donostia, San Sebasti&#xe1;n, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eizaguirre-Letamendia</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General y Digestiva, Secci&#xf3;n de Cirug&#xed;a Esofagog&#xe1;strica y Obesidad, Hospital Universitario Donostia, San Sebasti&#xe1;n, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murgoitio-Lazkano</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General y Digestiva, Secci&#xf3;n de Cirug&#xed;a Esofagog&#xe1;strica y Obesidad, Hospital Universitario Donostia, San Sebasti&#xe1;n, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arana-I&#xf1;iguez</LastName><ForeName>&#xcd;&#xf1;igo</ForeName><Initials>&#xcd;</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General y Digestiva, Secci&#xf3;n de Cirug&#xed;a Esofagog&#xe1;strica y Obesidad, Hospital Universitario Donostia, San Sebasti&#xe1;n, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enr&#xed;quez-Navascu&#xe9;s</LastName><ForeName>Jos&#xe9; M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General y Digestiva, Secci&#xf3;n de Cirug&#xed;a Esofagog&#xe1;strica y Obesidad, Hospital Universitario Donostia, San Sebasti&#xe1;n, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Unexpected diagnosis in a patient with suspected GIST: gastric infiltration due to multiple myeloma.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D046152" MajorTopicYN="Y">Gastrointestinal Stromal Tumors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009101" MajorTopicYN="Y">Multiple Myeloma</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Est&#xf3;mago</Keyword><Keyword MajorTopicYN="N">GIST</Keyword><Keyword MajorTopicYN="N">Hemorragia</Keyword><Keyword MajorTopicYN="N">Hemorrhage</Keyword><Keyword MajorTopicYN="N">Mieloma</Keyword><Keyword MajorTopicYN="N">Stomach</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>7</Day><Hour>12</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33284264</ArticleId><ArticleId IdType="doi">10.24875/CIRU.20000566</ArticleId><ArticleId IdType="pii">j88/Suppl 2/90</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32553661</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5778</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Actas dermo-sifiliograficas</Title><ISOAbbreviation>Actas Dermosifiliogr (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Neoplastic Cutaneous Infiltration by Lymphoplasmacytic Lymphoma in a Patient with Waldenstr&#xf6;m's Macroglobulinemia.</ArticleTitle><Pagination><StartPage>528</StartPage><EndPage>531</EndPage><MedlinePgn>528-531</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ad.2018.09.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0001-7310(20)30112-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valejo Coelho</LastName><ForeName>M M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Servicio de Dermatolog&#xed;a y Venereolog&#xed;a, Centro Hospitalar Universit&#xe1;rio de Lisboa Central, Lisboa, Portugal. Electronic address: margarida.m.v.coelho@chlc.min-saude.pt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo&#xe3;o</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Dermatolog&#xed;a y Venereolog&#xed;a, Centro Hospitalar Universit&#xe1;rio de Lisboa Central, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha P&#xe1;ris</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Servicio de Dermatolog&#xed;a y Venereolog&#xed;a, Centro Hospitalar Universit&#xe1;rio de Lisboa Central, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Infiltraci&#xf3;n neopl&#xe1;sica cut&#xe1;nea por un linfoma linfoplasmoc&#xed;tico en una paciente con macroglobulinemia de Waldenstr&#xf6;m.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Dermosifiliogr (Engl Ed)</MedlineTA><NlmUniqueID>101777537</NlmUniqueID><ISSNLinking>2173-5778</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008223" MajorTopicYN="Y">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008258" MajorTopicYN="Y">Waldenstrom Macroglobulinemia</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32553661</ArticleId><ArticleId IdType="doi">10.1016/j.ad.2018.09.027</ArticleId><ArticleId IdType="pii">S0001-7310(20)30112-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30361719</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>6</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>[Morbilidad y mortalidad de la linfadenectom&#xed;a cervical. An&#xe1;lisis de 311 casos].</ArticleTitle><Pagination><StartPage>522</StartPage><EndPage>527</EndPage><MedlinePgn>522-527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.18000311</ELocationID><Abstract><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Determinar la morbimortalidad y los factores de riesgo asociados a la linfadenectom&#xed;a cervical.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Estudio transversal anal&#xed;tico en el que se incluyeron pacientes sometidos a linfadenectom&#xed;a cervical en cualquiera de sus variantes, secundarios a la recurrencia de alguna enfermedad neopl&#xe1;sica, desde enero de 2011 hasta noviembre de 2016.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Se incluyeron 311 pacientes, de los cuales 203 (65.3%) eran mujeres, con una edad de 49 &#xb1; 17.2 a&#xf1;os. Los diagn&#xf3;sticos m&#xe1;s frecuentes fueron c&#xe1;ncer de tiroides, en 194 (62.4%) casos, y c&#xe1;ncer de laringe recurrente, en 22 (7.1%). Cursaron asintom&#xe1;ticos 166 (53.4%) pacientes, y 119 (38.3%) presentaron masas o n&#xf3;dulos en el cuello, siendo el nivel III el m&#xe1;s afectado, con 276 (88.7%) pacientes. La morbilidad general fue del 17% y la mortalidad fue del 5.8%. Los factores relacionados con la mortalidad fueron la sintomatolog&#xed;a presente (p = 0.006), la afectaci&#xf3;n del nivel I (p = 0.005), la disecci&#xf3;n ganglionar extensa (p = 0.01) y las complicaciones vasculares (p = 0.0001) y de la herida (p = 0.01).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">Debido al patr&#xf3;n de diseminaci&#xf3;n linf&#xe1;tica de los tumores de cabeza y cuello, la linfadenectom&#xed;a selectiva desempe&#xf1;a un papel crucial en su tratamiento. Se ha optado por la realizaci&#xf3;n de cirug&#xed;as m&#xe1;s conservadoras, siempre y cuando sean preservados los principales objetivos oncol&#xf3;gicos.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the morbidity and mortality and the risk factors associated with cervical lymphadenectomy.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Cross-sectional study; patients undergoing cervical lymphadenectomy were included in any of its variants, secondary to the recurrence of some neoplastic entity; from January 2011 to November 2016.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">311 patients were included of which 65.3% were women and 49 &#xb1; 17.2 years old. The most frequent diagnoses were thyroid cancer 194 (62.4%) and recurrent laryngeal cancer 22 (7.1%). Asymptomatic patients had 53.4% of the patients and 119 (38.3%) presented masses or nodules in the neck, with level III being the most affected with 276 (88.7%) patients. Overall morbidity was 17% and mortality was 5.8%. The factors related to mortality were: present symptomatology (p = 0.006), involvement of level I (p = 0.005), extensive lymph node dissection (p = 0.01), and vascular complications (p = 0.0001) and the wound (p = 0.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Due to the lymphatic dissemination pattern of head and neck tumors, selective lymphadenectomy plays a crucial role in the treatment of these neoplasms. We have opted to perform more conservative surgeries, as long as the main oncological objectives are preserved.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2018 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Vargas</LastName><ForeName>H&#xe9;ctor</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a Oncol&#xf3;gica. Unidad M&#xe9;dica de Alta Especialidad, Hospital de Especialidades del Centro M&#xe9;dico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortes-Torres</LastName><ForeName>Edgar J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a Oncol&#xf3;gica. Unidad M&#xe9;dica de Alta Especialidad, Hospital de Especialidades del Centro M&#xe9;dico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Ojeda</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n Biom&#xe9;dica. Unidad M&#xe9;dica de Alta Especialidad, Hospital de Especialidades del Centro M&#xe9;dico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Landeros</LastName><ForeName>Jacob E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n Biom&#xe9;dica. Unidad M&#xe9;dica de Alta Especialidad, Hospital de Especialidades del Centro M&#xe9;dico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrera-L&#xf3;pez</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n Biom&#xe9;dica. Unidad M&#xe9;dica de Alta Especialidad, Hospital de Especialidades del Centro M&#xe9;dico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes-Orozco</LastName><ForeName>Clotilde</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n Biom&#xe9;dica. Unidad M&#xe9;dica de Alta Especialidad, Hospital de Especialidades del Centro M&#xe9;dico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Morbidity and mortality of cervical lymphenectomy. Analysis of 311 cases.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037981" MajorTopicYN="N">Neck Dissection</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical lymphadenectomy</Keyword><Keyword MajorTopicYN="N">Ganglion levels</Keyword><Keyword MajorTopicYN="N">Linfadenectom&#xed;a cervical</Keyword><Keyword MajorTopicYN="N">Morbidity</Keyword><Keyword MajorTopicYN="N">Morbilidad</Keyword><Keyword MajorTopicYN="N">Mortalidad</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Niveles ganglionares</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30361719</ArticleId><ArticleId IdType="doi">10.24875/CIRU.18000311</ArticleId><ArticleId IdType="pii">j86/6/522</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27462886</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2317-6385</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Einstein (Sao Paulo, Brazil)</Title><ISOAbbreviation>Einstein (Sao Paulo)</ISOAbbreviation></Journal><ArticleTitle>The destruction complex of beta-catenin in colorectal carcinoma and colonic adenoma.</ArticleTitle><Pagination><StartPage>135</StartPage><EndPage>142</EndPage><MedlinePgn>135-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/S1679-45082016AO3678</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1679-45082016000200006</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the destruction complex of beta-catenin by the expression of the proteins beta-catetenin, adenomatous polyposis coli, GSK3&#x3b2;, axin and ubiquitin in colorectal carcinoma and colonic adenoma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Tissue samples from 64 patients with colorectal carcinoma and 53 patients with colonic adenoma were analyzed. Tissue microarray blocks and slides were prepared and subjected to immunohistochemistry with polyclonal antibodies in carcinoma, adjacent non-neoplastic mucosa, and adenoma tissues. The immunoreactivity was evaluated by the percentage of positive stained cells and by the intensity assessed through of the stained grade of proteins in the cytoplasm and nucleus of cells. In the statistical analysis, the Spearman correlation coefficient, Student's t, &#x3c7;2, Mann-Whitney, and McNemar tests, and univariate logistic regression analysis were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In colorectal carcinoma, the expressions of beta-catenin and adenomatous polyposis coli proteins were significantly higher than in colonic adenomas (p&lt;0.001 and p&lt;0.0001, respectively). The immunoreactivity of GSK3&#x3b2;, axin 1 and ubiquitin proteins was significantly higher (p=0.03, p=0.039 and p=0.03, respectively) in colorectal carcinoma than in the colonic adenoma and adjacent non-neoplastic mucosa. The immunohistochemistry staining of these proteins did not show significant differences with the clinical and pathological characteristics of colorectal cancer and colonic adenoma.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest that, in adenomas, the lower expression of the beta-catenin, axin 1 and GSK3&#x3b2; proteins indicated that the destruction complex of beta-catenin was maintained, while in colorectal carcinoma, the increased expression of beta-catenin, GSK3&#x3b2;, axin 1, and ubiquitin proteins indicated that the destruction complex of beta-catenin was disrupted.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Avaliar o complexo de destrui&#xe7;&#xe3;o da betacatenina no carcinoma colorretal e no adenoma do colo pela express&#xe3;o das prote&#xed;nas betacatenina, adenomatous polyposis coli, GSK3&#x3b2;, axina e ubiquitina.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Amostras de tecidos de 64 doentes com carcinoma colorretal e de 53 pacientes com adenoma do colo foram analisadas. Blocos de tecidos foram submetidos ao estudo imuno-histoqu&#xed;mico com anticorpos policlonais nos tecidos do carcinoma, mucosa n&#xe3;o neopl&#xe1;sica adjacente e adenoma. A imunorreatividade foi avaliada pela porcentagem de positividade de c&#xe9;lulas coradas e pela intensidade do grau de colora&#xe7;&#xe3;o das prote&#xed;nas no citoplasma e no n&#xfa;cleo das c&#xe9;lulas. Na an&#xe1;lise estat&#xed;stica, foram utilizados o coeficiente de correla&#xe7;&#xe3;o de Spearman, os testes t de Student, &#x3c7;2, Mann-Whitney e de McNemar, e a an&#xe1;lise de regress&#xe3;o log&#xed;stica univariada.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">No carcinoma colorretal, as express&#xf5;es da betacatenina e da adenomatous polyposis coli foram significativamente maiores do que em adenomas do colo (p&lt;0,001 e p&lt;0,0001, respectivamente). A imunorreatividade das prote&#xed;nas GSK3&#x3b2;, axina 1 e ubiquitina foi significativamente maior (p=0,03, p=0,039 e p=0,03, respectivamente) no carcinoma colorretal do que no adenoma e na mucosa n&#xe3;o neopl&#xe1;sica adjacente. A colora&#xe7;&#xe3;o imuno-histoqu&#xed;mica dessas prote&#xed;nas n&#xe3;o apresentou diferen&#xe7;as significantes em rela&#xe7;&#xe3;o &#xe0;s caracter&#xed;sticas clinicopatol&#xf3;gicas do c&#xe2;ncer colorretal e do adenoma.</AbstractText><AbstractText Label="CONCLUS&#xd5;ES" NlmCategory="UNASSIGNED">Em adenomas, as menores express&#xf5;es de betacatenina, axina 1 e GSK3&#x3b2; indicaram que o complexo de destrui&#xe7;&#xe3;o da betacatenina estava conservado, enquanto que, no carcinoma colorretal, o aumento das express&#xf5;es da betacatenina, GSK3&#x3b2;, 1 axina, e ubiquitina indicaram que o complexo de destrui&#xe7;&#xe3;o de betacatenina estava alterado.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bourroul</LastName><ForeName>Guilherme Muniz</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Hospital do Servidor P&#xfa;blico Estadual "Francisco Morato de Oliveira", S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fragoso</LastName><ForeName>H&#xe9;lio Jos&#xe9;</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Hospital do Servidor P&#xfa;blico Estadual "Francisco Morato de Oliveira", S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Jos&#xe9; Walter Feitosa</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Hospital do Servidor P&#xfa;blico Estadual "Francisco Morato de Oliveira", S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourroul</LastName><ForeName>Vivian Sati Oba</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Hospital do Servidor P&#xfa;blico Estadual "Francisco Morato de Oliveira", S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oshima</LastName><ForeName>Celina Tizuko Fujiyama</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Thiago Sim&#xe3;o</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saba</LastName><ForeName>Gabriela Tognini</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina do ABC, Santo Andr&#xe9;, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palma</LastName><ForeName>Rog&#xe9;rio Tadeu</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Hospital do Servidor P&#xfa;blico Estadual "Francisco Morato de Oliveira", S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waisberg</LastName><ForeName>Jaques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital do Servidor P&#xfa;blico Estadual "Francisco Morato de Oliveira", S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>por</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Einstein (Sao Paulo)</MedlineTA><NlmUniqueID>101281800</NlmUniqueID><ISSNLinking>1679-4508</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C555451">AXIN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060466">Axin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060465">Axin Signaling Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000236" MajorTopicYN="N">Adenoma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011125" MajorTopicYN="N">Adenomatous Polyposis Coli</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060466" MajorTopicYN="N">Axin Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060465" MajorTopicYN="N">Axin Signaling Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002277" MajorTopicYN="N">Carcinoma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="OBJETIVO">Avaliar o complexo de destrui&#xe7;&#xe3;o da betacatenina no carcinoma colorretal e no adenoma do colo pela express&#xe3;o das prote&#xed;nas betacatenina, <i>adenomatous polyposis coli</i>, GSK3&#x3b2;, axina e ubiquitina.</AbstractText><AbstractText Label="M&#xc9;TODOS">Amostras de tecidos de 64 doentes com carcinoma colorretal e de 53 pacientes com adenoma do colo foram analisadas. Blocos de tecidos foram submetidos ao estudo imuno-histoqu&#xed;mico com anticorpos policlonais nos tecidos do carcinoma, mucosa n&#xe3;o neopl&#xe1;sica adjacente e adenoma. A imunorreatividade foi avaliada pela porcentagem de positividade de c&#xe9;lulas coradas e pela intensidade do grau de colora&#xe7;&#xe3;o das prote&#xed;nas no citoplasma e no n&#xfa;cleo das c&#xe9;lulas. Na an&#xe1;lise estat&#xed;stica, foram utilizados o coeficiente de correla&#xe7;&#xe3;o de Spearman, os testes <i>t</i> de <i>Student</i>, &#x3c7;<sup>2</sup>, Mann-Whitney e de McNemar, e a an&#xe1;lise de regress&#xe3;o log&#xed;stica univariada.</AbstractText><AbstractText Label="RESULTADOS">No carcinoma colorretal, as express&#xf5;es da betacatenina e da <i>adenomatous polyposis coli</i> foram significativamente maiores do que em adenomas do colo (p&lt;0,001 e p&lt;0,0001, respectivamente). A imunorreatividade das prote&#xed;nas GSK3&#x3b2;, axina 1 e ubiquitina foi significativamente maior (p=0,03, p=0,039 e p=0,03, respectivamente) no carcinoma colorretal do que no adenoma e na mucosa n&#xe3;o neopl&#xe1;sica adjacente. A colora&#xe7;&#xe3;o imuno-histoqu&#xed;mica dessas prote&#xed;nas n&#xe3;o apresentou diferen&#xe7;as significantes em rela&#xe7;&#xe3;o &#xe0;s caracter&#xed;sticas clinicopatol&#xf3;gicas do c&#xe2;ncer colorretal e do adenoma.</AbstractText><AbstractText Label="CONCLUS&#xd5;ES">Em adenomas, as menores express&#xf5;es de betacatenina, axina 1 e GSK3&#x3b2; indicaram que o complexo de destrui&#xe7;&#xe3;o da betacatenina estava conservado, enquanto que, no carcinoma colorretal, o aumento das express&#xf5;es da betacatenina, GSK3&#x3b2;, 1 axina, e ubiquitina indicaram que o complexo de destrui&#xe7;&#xe3;o de betacatenina estava alterado.</AbstractText></OtherAbstract><CoiStatement>Conflict of interest: none.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27462886</ArticleId><ArticleId IdType="pmc">PMC4943346</ArticleId><ArticleId IdType="doi">10.1590/S1679-45082016AO3678</ArticleId><ArticleId IdType="pii">S1679-45082016000200006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xue B, Dunker AK, Uversky VN. The roles of intrinsic disorder in orchestrating the Wnt-pathway. J Biomol Struct Dyn. 2012;29(5):843&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">22292947</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries A, Cereser B, Gay LJ, Miller DS, Das B, Gutteridge A, et al. Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proc Natl Acad Sci U S A. 2013;110(27):E2490&#x2013;E2499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704042</ArticleId><ArticleId IdType="pubmed">23766371</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veelen W, Le NH, Helvensteijn W, Blonden L, Theeuwes M, Bakker ER, et al. &#x3b2;-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut. 2011;60(9):1204&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3152867</ArticleId><ArticleId IdType="pubmed">21307168</ArticleId></ArticleIdList></Reference><Reference><Citation>White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/&#x3b2;-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142(2):219&#x2013;232. Review.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285553</ArticleId><ArticleId IdType="pubmed">22155636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanczuga-Koda L, Wincewicz A, Fudala A, Abrycki T, Famulski W, Baltaziak M, et al. E-cadherin and &#x3b2;-catenin adhesion proteins correlate positively with connexins in colorectal cancer. Oncol Lett. 2014;7(6):1863&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049722</ArticleId><ArticleId IdType="pubmed">24932249</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao XP, Pretlow TG, Rao JS, Pretlow TP. Beta-catenin expression is altered in human colon aberrant cript foci. Cancer Res. 2001;61(22):8085&#x2013;8088.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719432</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Dou QP. The ubiquitin-proteosome system as a prospective molecular target for cancer treatment and prevention. Curr Protein Pept Sci. 2010;11(6):459&#x2013;470. Review.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306609</ArticleId><ArticleId IdType="pubmed">20491623</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmit SL, Figueiredo JC, Cortessis VK, Thomas DC. The influence of screening for precancerous lesions on family-based genetic association tests: an example of colorectal polyps and cancer. Am J Epidemiol. 2015;182(8):714&#x2013;722. Erratum in: Am J Epidemiol. 2016;183(3):248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4597802</ArticleId><ArticleId IdType="pubmed">26306664</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrocea FL, Sajin M, Marinescu EC, Stoica D. Colorectal cancer and the 7th revision of the TNM staging system: review of changes and suggestions for uniform pathologic reporting. Rom J Morphol Embryol. 2011;52(2):537&#x2013;544. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">21655640</ArticleId></ArticleIdList></Reference><Reference><Citation>Matos LL, Stabenow E, Tavares MR, Ferraz AR, Capelozzi VL, Pinhal MA. Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis. Clinics (Sao Paulo) 2006;61(5):417&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">17072439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TM, An CH, Rhee JK, Jung SH, Lee SH, Baek IP, et al. Clonal origins and parallel evolution of regionally synchronous colorectal adenoma and carcinoma. Oncotarget. 2015;6(29):27725&#x2013;27735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4695021</ArticleId><ArticleId IdType="pubmed">26336987</ArticleId></ArticleIdList></Reference><Reference><Citation>Minde DP, Anvarian Z, R&#xfc;diger SG, Maurice MM. Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? 101Mol Cancer. 2011;10 Review.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170638</ArticleId><ArticleId IdType="pubmed">21859464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata DC, Greca FH, Luz Mde A, Ioshii SO, Tomasich FD. Aberrant crypt foci and cancer of the colorectal junction: the correlation between beta-catenin/Ki-67 expression and the occurrence of early microscopic secondary lesions surrounding periphery colorectal cancer. Rev Col Bras Cir. 2010;37(2):114&#x2013;120. Portuguese.</Citation><ArticleIdList><ArticleId IdType="pubmed">20549101</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng TH, Gorman M, Martin L, Barclay E, Casey G, Colon Cancer Family Registry. CGEMS. Saunders B, Thomas H, Clark S, Tomlinson I. Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP. Eur J Hum Genet. 2015;23(2):260&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140766</ArticleId><ArticleId IdType="pubmed">24801760</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamulla RJ, Kane EG, Moody AE, Politi KA, Lock NE, Foley AV, et al. Testing models of the APC tumor suppressor/&#x3b2;-catenin interaction reshapes our view of the destruction complex in Wnt signaling. Genetics. 2014;197(4):1285&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4125400</ArticleId><ArticleId IdType="pubmed">24931405</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio CA, Kaufeldt A, Koha R, Ushoida M, Lindahl J, Kis LL. &#x3b2;-catenin helices in the cytoplasm of sessile serrated adenoma/polyps and conventional colorectal adenomas. Anticancer Res. 2015;35(2):929&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pubmed">25667476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahearn TU, Shaukat A, Flanders WD, Seabrook ME, Bostick RM. Markers of the APC/&#x3b2;-catenin signaling pathway as potential treatable, preneoplastic biomarkers of risk for colorectal neoplasms. Cancer Epidemiol Biomarkers Prev. 2012;21(6):969&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">22539608</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Fu X, Zhang W, Xiao L, Qiu Y, Peng Y, et al. Wnt signaling pathway is activated in right colon serrated polyps correlating to specific molecular form of &#x3b2;-catenin. Hum Pathol. 2013;44(6):1079&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">23317545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HL, Peters U, Hayes RB, Huang WY, Schatzkin A, Bresalier RS, et al. Polymorphisms in the adenomatous polyposis coli (APC) gene and advanced colorectal adenoma risk. Eur J Cancer. 2010;46(13):2457&#x2013;2466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924917</ArticleId><ArticleId IdType="pubmed">20510605</ArticleId></ArticleIdList></Reference><Reference><Citation>Salim T, Sj&#xf6;lander A, Sand-Dejmek J. Nuclear expression of glycogen synthase kinase-3&#x3b2; and lack of membranous &#x3b2;-catenin is correlated with poor survival in colon cancer. Int J Cancer. 2013;133(4):807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">23389968</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HL, Hart J, Fan L, Mustafi R, Bissonnette M. Upregulation of glycogen synthase kinase 3&#x3b2; in human colorectal adenocarcinomas correlates with accumulation of CTNNB1. Clin Colorectal Cancer. 2011;10(1):30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">21609933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NH, Cha YH, Kang SE, Lee Y, Lee I, Cha SY, et al. p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells. Cell Cycle. 2013;12(10):1578&#x2013;1587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680537</ArticleId><ArticleId IdType="pubmed">23624843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Hou W, Wang HL, Liu HJ, Jia XY, Zheng XZ, et al. GSK-3&#x3b2;-regulated N-acetyltransferase 10 is involved in colorectal cancer invasion. Clin Cancer Res. 2014;20(17):4717&#x2013;4729.</Citation><ArticleIdList><ArticleId IdType="pubmed">24982245</ArticleId></ArticleIdList></Reference><Reference><Citation>Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, et al. Wnt signaling through inhibition of &#x3b2;-catenin degradation in an intact Axin1 complex. Cell. 2012;149(6):1245&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">22682247</ArticleId></ArticleIdList></Reference><Reference><Citation>Parveen N, Hussain MU, Pandith AA, Mudassar S. Diversity of axin in signaling pathways and its relation to colorectal cancer. Med Oncol. 2011;28(Suppl 1):S259&#x2013;S267. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">21053101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwak J, Hwang SG, Park HS, Choi SR, Park SH, Kim H, et al. Small molecule-based disruption of the Axin/ &#x3b2;-catenin protein complex regulates mesenchymal stem cell differentiation. Cell Res. 2012;22(1):237&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351914</ArticleId><ArticleId IdType="pubmed">21826110</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiedler M, Mendoza-Topaz C, Rutherford TJ, Mieszczanek J, Bienz M. Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating &#x3b2;-catenin. Proc Natl Acad Sci U S A. 2011;108(5):1937&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033301</ArticleId><ArticleId IdType="pubmed">21245303</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauriello DV, Maurice MM. The various roles of ubiquitin in Wnt pathway regulation. Cell Cycle. 2010;9(18):3700&#x2013;3709. Review.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047798</ArticleId><ArticleId IdType="pubmed">20930545</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan DW, Li DW, Yang YX, Xia J, Wang XL, Zhou CZ, et al. Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery. Br J Cancer. 2010;103(7):961&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965875</ArticleId><ArticleId IdType="pubmed">20808312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Jiang T, Tang H, Cui F, Liu C, Guo F, et al. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy. J Gastroenterol Hepatol. 2015;30(4):680&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">25238407</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22658549</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0375-0906</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Revista de gastroenterologia de Mexico</Title><ISOAbbreviation>Rev Gastroenterol Mex</ISOAbbreviation></Journal><ArticleTitle>[Hyperplastic polyp with neoplastic transformation in a patient with atrophic gastritis and multiple gastric neuroendocrine tumors].</ArticleTitle><Pagination><StartPage>96</StartPage><EndPage>98</EndPage><MedlinePgn>96-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rgmx.2012.03.002</ELocationID><Abstract><AbstractText>Hyperplastic gastric polyps are often found at GI endoscopy and are not considered premalignant lesions, although some cases of malignancy have been reported. Neuroendocrine tumors, conversely, are rare and account for approximately 1% to 2% of gastric polyps. Both hyperplastic gastric polyps and neuroendocrine tumors are related to gastric atrophy. The case of a hyperplastic polyp with multifocal areas of adenocarcinoma within the polyp associated to multiple gastric neuroendocrine tumors is reported.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Asociaci&#xf3;n Mexicana de Gastroenterolog&#xed;a. Published by Elsevier Espa&#xf1;a. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moura</LastName><ForeName>E G H</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Unidad de Endoscopia Gastrointestinal, Facultad de Medicina, Universidad de Sao Paulo, Sao Paulo, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domingos</LastName><ForeName>T A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Alvarado</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Iriya</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kishi</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>B C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Moura</LastName><ForeName>E T H</ForeName><Initials>ET</Initials></Author><Author ValidYN="Y"><LastName>P</LastName><ForeName>P Sakai</ForeName><Initials>PS</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>P&#xf3;lipo hiperpl&#xe1;sico con transformaci&#xf3;n neopl&#xe1;sica en paciente con gastritis atr&#xf3;fica y m&#xfa;ltiples tumores neuroendocrinos.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Gastroenterol Mex</MedlineTA><NlmUniqueID>0404271</NlmUniqueID><ISSNLinking>0375-0906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005755">Gastrins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005755" MajorTopicYN="N">Gastrins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005757" MajorTopicYN="N">Gastritis, Atrophic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016481" MajorTopicYN="N">Helicobacter Infections</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016480" MajorTopicYN="N">Helicobacter pylori</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018358" MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011127" MajorTopicYN="N">Polyps</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22658549</ArticleId><ArticleId IdType="doi">10.1016/j.rgmx.2012.03.002</ArticleId><ArticleId IdType="pii">S0375-0906(12)00006-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>